PROCEPT BioRobotics Corporation (PRCT) – What Are Brokerages Saying About This Stock?

PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Get Free Report) has earned an average rating of “Hold” from the sixteen research firms that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation, two have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $25.25.

PRCT has been the subject of a number of analyst reports. Jefferies Financial Group reiterated a “hold” rating and issued a $20.00 price target on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Oppenheimer reissued a “market perform” rating on shares of PROCEPT BioRobotics in a report on Wednesday, September 9th. Truist Financial boosted their price objective on PROCEPT BioRobotics from $21.00 to $24.00 and gave the company a “hold” rating in a research report on Friday, November 6th. William Blair lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Finally, TD Cowen cut their target price on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, August 5th.

Read Our Latest Report on PROCEPT BioRobotics

Insider Buying and Selling

In related news, insider Pooja Sharma sold 4,710 shares of the business’s stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $19.71, for a total value of $92,834.10. Following the transaction, the insider directly owned 106,471 shares of the company’s stock, valued at approximately $2,098,543.41. The trade was a 4.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 5,753 shares of company stock valued at $114,685. 4.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On PROCEPT BioRobotics

Institutional investors and hedge funds have recently modified their holdings of the stock. Center for Financial Planning Inc. lifted its holdings in shares of PROCEPT BioRobotics by 59.6% in the 1st quarter. Center for Financial Planning Inc. now owns 2,040 shares of the company’s stock worth $51,000 after acquiring an additional 762 shares during the last quarter. Versant Capital Management Inc grew its stake in shares of PROCEPT BioRobotics by 70.3% during the third quarter. Versant Capital Management Inc now owns 2,032 shares of the company’s stock valued at $37,000 after buying an additional 839 shares during the last quarter. Signaturefd LLC grew its stake in shares of PROCEPT BioRobotics by 162.7% during the third quarter. Signaturefd LLC now owns 1,899 shares of the company’s stock valued at $35,000 after buying an additional 1,176 shares during the last quarter. Nykredit A S purchased a new stake in shares of PROCEPT BioRobotics in the second quarter worth approximately $27,000. Finally, Parallel Advisors LLC raised its holdings in shares of PROCEPT BioRobotics by 51.8% in the third quarter. Parallel Advisors LLC now owns 3,656 shares of the company’s stock worth $67,000 after buying an additional 1,247 shares during the period. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Stock Performance

PRCT opened at $23.80 on Monday. The firm has a market cap of $1.37 billion, a P/E ratio of -11.78 and a beta of 0.88. PROCEPT BioRobotics has a 1-year low of $16.67 and a 1-year high of $38.11. The company has a 50 day simple moving average of $19.52 and a two-hundred day simple moving average of $22.95. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.89 and a quick ratio of 4.73.

PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07). PROCEPT BioRobotics had a negative return on equity of 33.23% and a negative net margin of 32.60%. The firm had revenue of $98.29 million during the quarter, compared to analysts’ expectations of $100.52 million. During the same period last year, the company earned ($0.38) earnings per share. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. Equities analysts forecast that PROCEPT BioRobotics will post -1.74 earnings per share for the current fiscal year.

About PROCEPT BioRobotics

(Get Free Report)

PROCEPT BioRobotics develops and commercializes surgical robotic systems for urology, with a focus on treating benign prostatic hyperplasia, or BPH, an enlargement of the prostate that can cause urinary symptoms. The company’s core offering is Aquablation therapy, delivered using its AquaBeam Robotic System. The procedure combines imaging guidance with a surgeon-controlled, robotically assisted waterjet to remove prostate tissue. PROCEPT also offers its HYDROS Robotic System, a platform designed to deliver Aquablation therapy.

Recommended Stories

Analyst Recommendations for PROCEPT BioRobotics (NASDAQ:PRCT)

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.